- Home
- CYRX vs RCKT Comparison
CYRX vs RCKT Comparison
Compare CYRX & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYRX | RCKT |
|---|---|---|
| Founded | 1999 | 1999 |
| Country | United States | United States |
| Employees | 1100 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 421.6M | 428.6M |
| IPO Year | 2008 | N/A |
Fundamental Metrics
Financial Performance| Metric | CYRX | RCKT |
|---|---|---|
| Price | $8.05 | $4.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 14 |
| Target Price | $12.94 | ★ $29.65 |
| AVG Volume (30 Days) | 341.9K | ★ 2.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 156.22 | N/A |
| EPS | ★ 1.40 | N/A |
| Revenue | ★ $176,177,000.00 | N/A |
| Revenue This Year | $9.71 | N/A |
| Revenue Next Year | $9.56 | N/A |
| P/E Ratio | $4.99 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.63 | $2.19 |
| 52 Week High | $11.45 | $8.91 |
Technical Indicators
Market Signals| Indicator | CYRX | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 37.26 | 60.56 |
| Support Level | $6.57 | $2.99 |
| Resistance Level | $8.45 | $4.51 |
| Average True Range (ATR) | 0.51 | 0.34 |
| MACD | 0.04 | 0.07 |
| Stochastic Oscillator | 25.71 | 57.31 |
Price Performance
Historical ComparisonAbout CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.